HBV genotypes and gene mutations in patients with liver failure after withdrawal of lamivudine

( views:390, downloads:0 )
Author:
ZHANG Xiao-hong(Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China)
LIN Bing-liang(Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China)
YANG Shao-ji(Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China)
GAO Zhi-liang(Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China)
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 1, Issue 02, 2008
DOI:
Key Word:
Liver failure;Lamivudine;Relapse;Genotype;Mutation

Abstract: Objective To investigate HBV genotypes and gene mutations in chrenic hepatitis B (CHB) patients with liver failure after lamivudine withdrawal. Methods Twenty four patients with relapsing CHB after lamivudine withdrawal were divided into liver failure group ( n = 12 ) and chronic hepatitis group ( n = 12 ). HBV DNA from these patients was amplified by PCR. The PCR products were cloned into PGEM-T vector and HBV DNA sequences were analyzed. Results In liver failure group, there were 6 sequences detected, in which 3 were of genotype B and 3 were of genotype C. In chronic hepatitis group, there were 9 sequences detected, in which 2 were of genotype B and 7 were of genotype C. Compared with the wild type HBV sequences, there were multiples mutations in S, P, C, X regions. Gene mutations in high conservative sequences of BCP and P regions were detected in liver failure patients after lamivudine withdrawal. Conclusions In HBV patients with liver failure after lamivudine withdrawal, half of them were of genotype B and the others were of genotype C. Some mutations in high conservative sequences of BCP and P regions may be related to the liver failure in these patients.

  • [1]Ciancio A,Smedile A,Rizzetto M,et al.Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.Hepatolngy,2004,39(1):64-73.
  • [2]Kan JH,Chen PJ,Lai MY,et al.Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.Gastroenterology,2000,118(3):554-559.
  • [3]Bottecchia M,Ikuta N,Niel C,et al.Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B vires associated with a fatal hepatic failure case.J Gastroentorol Hepatol,2008,23(1):67-72.
  • [4]Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association.The programme of prevention and cure for viral hepatitis.Zhonghua Ganzanghing Zazhi,2000,8(6):324-329.中华医学会传染病与寄生虫病学分会、肝脏病学分会.病毒性肝炎防治方案.中华肝脏病杂志,2000,8(6):324-329.
  • [5]Huang J,Gao ZL.The clinical significance of hepatitis B virus genotypes.Shijie Huaren Xiaohua Zazhi,2002,10(11):1362-1364.黄晶.高志良.乙型肝炎病毒基因型及其临床意义的研究.世界华人消化杂志,2002,10(11):1362-1364.
  • [6]Lindh M,Hannoun C,Dhillon AP,et al.Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers.J Infect Dis,1999,179 (4):775 -782.
  • [7]Yuen MF,Tanaka Y,Lai CL.Hepatitis B genotypes in chronic hepatitis B and lamivudins therapy,Intervirology,2003,46(6):373-376.
  • [8]Pan XP,Li LJ,Du WB,et al.Differences of YMDD mutational patterns,precore/core promoter mutations,scram HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.J Viral Hepat,2007,14(11):767-774.
  • [9]Warner N,Locamini S,Kuiper M,et al.The rtLSOi substitution in the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.Antimicrob Agents Chemother,2007,51(7):2285-2292.
  • [10]Yatsuji H,Noguchi C,Hiraga N,et al.Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.Antinucroh Agents Chemother,2006,50 (11):3867-3874.
  • [11]Neau D,Schvoerer E,Robert D,et al.Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodefieiency vires-infected patient.J Infect,2000,41(2):192-194.
  • [12]Lim SG,Wai CT,Rajnakova A,et al.Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.Gut,2002,51(4):597-599.
  • [13]Li J,Zhu LM,Liang SR,et al.Relationship between the HBV core gone mutation and the cellular immunity in host.Zhonghua Ganzangbing Zazhi,2003,11(9):533-535.李嘉,朱理珉,梁树人,等.乙型肝炎病毒核心区基因变异与细胞免疫.中华肝脏病杂志,2003,11(9):533-535.
  • [14]Yotsuyanagi H,Hino K,Tomita E,et al.Precore and core promoter mutations,hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B.J Hepatol,2002,37(3):355-363.
  • [15]Guo YB,Feng XR,Dai W,et al.Effect of mutation (T1762A1764) on hepatitis B virus core promoter activity.Zhonghua Ganzanghing Zazhi,1999,7(1):15-16.郭亚兵,冯筱榕,戴炜,等.T1762A1764变异对乙型肝炎病毒C启动子活性影响.中华肝脏病杂志,1999,7(1):15-16.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn